Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03923374 · ClinicalTrials.gov registry record

Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes

A clinical trial of Opioid Use Disorder and Opioid Use, Unspecified, sponsored by Senthil Sadhasivam.

Recruiting
Registry status
600
Enrollment target
1
Study location

NCT03923374 is a study of Opioid Use Disorder and Opioid Use, Unspecified that is actively recruiting participants, run by Senthil Sadhasivam. The registered enrollment target is 600 participants, below the 4,654-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03923374, a study of Opioid Use Disorder and Opioid Use, Unspecified, is actively recruiting participants, sponsored by Senthil Sadhasivam.

RECRUITING
Registry status
600 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to better understand the comprehensive integration of both clinical and genetic factors that will help to identify mothers who could be at an increased risk of poor response to opioid substitution and infants at risk of significant neonatal abstinence syndrome (NAS).

Interventions

  • DRUG Subutex / Buprenorphine
  • DIAGNOSTIC_TEST Fetal & Neonatal MRI
  • DIAGNOSTIC_TEST DNA/Genetic/Pharmacokenetic Blood Draws

Study Locations (1)

Pennsylvania

  • UPMC Children's Hospital - Pittsburgh

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2018-09-15
Est. Completion 2026-12-30

Sponsor

Senthil Sadhasivam

7 total trials

What the Registry Record Tells You About NCT03923374

The ClinicalTrials.gov registry entry for NCT03923374 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,654-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (87% lower). The listed sponsor is Senthil Sadhasivam, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Subutex / Buprenorphine is the first listed.

NCT03923374 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03923374 about?

NCT03923374 is a clinical study titled "Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes". The objective of this study is to better understand the comprehensive integration of both clinical and genetic factors that will help to identify mothers who could be at an increased risk of poor response to opioid substitution and infants at risk of significant neonatal abstinence syndrome (NAS).

What is the current status of trial NCT03923374?

This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2018-09-15. Estimated completion is 2026-12-30.

What conditions does trial NCT03923374 study?

This clinical trial studies the following conditions: Opioid Use Disorder, Opioid Use, Unspecified, Buprenorphine Dependence.

What interventions are being tested in trial NCT03923374?

The interventions under investigation include: Subutex / Buprenorphine (DRUG), Fetal & Neonatal MRI (DIAGNOSTIC_TEST), DNA/Genetic/Pharmacokenetic Blood Draws (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03923374?

This trial is sponsored by Senthil Sadhasivam, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03923374 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.